Thomas wrote: One thing freaked me out it bit and that is what I read about IBD Inflammatory bowel disease. Why did I look into that, well because I have exactly the symptoms. here I read: But in people with IBD, the immune system seems to overreact to normal bacteria in the digestive tract. And once it starts working, the immune system fails to “shut off.” This causes the inflammation, which damages the digestive tract and causes symptoms. the bold outline text is the part where I got afraid about. What is if I cant have good strong Probiotics because my immune system freaks out with them. If that is the case I am really in shit. What do you think Able.
Thomas; do you remember when you first stated researching Candida and reading tons of information and noticing how many different sites you read about what will and what will not cure the infestation? Way over half of them really didn’t have a clue, right? Well guess what, it’s the same for any disease you can name. There are hundreds of people on the net who think they have the end all answer but have never bothered to find actual research proving or disproving their theory. We can say the very same about Inflammatory Bowel Disease, there are lots of people who don’t have a clue as far as the research conducted, yet they’re telling people they have the answer.
The article below was published in the Journal of Medical Microbiology. The article is about butyric acid producing bacteria, and at least two of the bacterial species which produce butyric acid are in most of the good quality probiotic brands, those are lactobacilli and bifidobacteria.
Promising Probiotic Treatment for Inflammatory Bowel Disease
“Bacteria that produce compounds to reduce inflammation and strengthen host defenses could be used to treat inflammatory bowel disease (IBD). Such probiotic microbes could be the most successful treatment for IBD to date.
IBD is inflammation of the gastro-intestinal tract that causes severe watery and bloody diarrhoea and abdominal pain. It is an emerging disease that affects 20 out of 100,000 genetically susceptible people in Europe and North America. The most common manifestations of IBD are Crohn’s disease and ulcerative colitis. While the exact causes are unclear, IBD is known to be the result of an overactive immune response that is linked to an imbalance of the normal types of bacteria found in the gut.
Several recent studies have identified butyric acid as a potential therapeutic agent for IBD. Some gut bacteria produce butyric acid naturally in the intestines, but in IBD patients some of these strains are heavily depleted. Trials in mice have shown that injecting one such strain Faecalibacterium prausnitzii into the digestive tract is effective at restoring normal levels of gut bacteria and treating the symptoms of IBD. In addition, novel identified butyrate-producing strains, such as Butyricicoccus pullicaecorum, have been shown to exert similar effects.
Butyric acid has well-known anti-inflammatory effects and is able to strengthen intestinal wall cells — making it an ideal therapeutic agent against IBD. In addition to butyric acid, it is hypothesized that strains such as F. prausnitzii and B.pullicaecorum secrete other anti-inflammatory compounds that may enhance the therapeutic effect.
Prof. Filip Van Immerseel, a medical microbiologist from Ghent University in Belgium said that a new treatment for IBD would be welcomed. “Conventional drug therapy has limited effectiveness and considerable side effects. Probiotics are live bacterial supplements or food ingredients, which when taken in sufficient numbers confer health benefits to the host,” he said. Previous trials of probiotics to treat IBD using mainly lactic acid bacteria have given mixed results. “Now we realize that lactic acid is used for growth by a certain population of bacteria that produce butyric acid, which could explain why some of the older studies had a positive outcome. Recent trials focusing on butyric acid-producing bacterial strains have been extremely promising and could lead to a new treatment for IBD.”
Developing an effective probiotic treatment for IBD will not be easy, however. “As butyric acid-producing bacteria are naturally depleted in IBD patients, we will need to identify strains that are able to colonize the gut without being outcompeted. Many bacterial species produce butyric acid and possibly other anti-inflammatory molecules so it’s a case of finding which is the most robust under these conditions,” said Prof. Van Immerseel.”